Frequency and risk factors for hydroxychloroquine retinopathy among patients with systemic lupus erythematosus

BACKGROUND: Hydroxychloroquine (HCQ) is an antimalarial drug, recently used in COVID-19 treatment. Also it is considered over many years the cornerstone in treating systemic lupus erythematosus (SLE) in adults and children. The incidence of retinal affection and retinal toxicity from hydroxychloroqu...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelbaky, Mohammed Salah Eldin, El Mamoun, Tarek Ahmad, Mabrouk, Fatma Ibrahim, Hassan, Rasha Mohamad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184260/
https://www.ncbi.nlm.nih.gov/pubmed/34121836
http://dx.doi.org/10.1186/s43162-021-00047-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184260/
https://www.ncbi.nlm.nih.gov/pubmed/34121836
http://dx.doi.org/10.1186/s43162-021-00047-y

Ejemplares similares